Active — Not RecruitingNot Applicable

Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema

China100 participantsStarted 2023-03-01

Plain-language summary

the goal of this observational study is to the find the molecular mechanisms underlying the prognosis process of Retinal vein occlusion in patients with retinal vein occlusion . The main question it aims to answer is: What are the changes in protein in the aqueous humor during treatment in patients who are sensitive to anti-VEGF drug therapy?

Who can participate

Age range

20 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Cystic or diffuse edema in the macular area, retinal vein tortuous dilation with hemorrhage * Optical coherence tomography (OCT) examination showed that the macular area was raised, edema and thickened * Monocular disease, baseline central retinal thickness (CRT) ≥ 250mm * Intravitreal injection, laser photocoagulation and blood circulation and blood stasis removal drugs were not treated before surgery * The patient had normal blood pressure, negative urine protein, normal liver and kidney function, and normal electrocardiogram Exclusion Criteria: * Patients with fluorescein fundus angiography (FFA) showing a large area (10 optic disc areas) without perfusion requiring retinal photocoagulation * Patients with chronic dacryocystitis, glaucoma, cataract, severe proliferative vitreoretinopathy or vitreous hemorrhage, epi macular membrane or macular ischemia, diabetic retinopathy, age-related macular degeneration, ocular trauma and other diseases * Intravitreal therapy or laser photocoagulation with corticosteroids or anti-VEGF drugs within three months before the study

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Central retinal thickness

Timeframe: March 2023 - June 2024

Trial details

NCT IDNCT07106268

SponsorTianjin Medical University Eye Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-09-30

View on ClinicalTrials.gov More Retinal Vein Occlusion trials